Biohaven forming subsidiary BioShin for Asia-Pacific market

Biohaven Pharmaceutical (BHVN) has advanced the formation of a wholly owned subsidiary, BioShin, a Shanghai based limited liability company, to develop and commercialize its late-stage migraine and neurology portfolio in China and other Asia-Pacific markets. Biohaven’s Chief of Corporate Strategy and Business Development, Donnie McGrath, has been appointed CEO of the new subsidiary which will be based in Shanghai. Previously, McGrath was Vice-President of Business Development and Head of Global Search and Evaluation at Bristol-Myers Squibb (BMY). Additional executive leaders appointed include Karl Lintel, COO, Zoey Wang, General Manager, and Elaine Hawkings, MSc, Head of Clinical Operations. BioShin plans to submit its first Investigational New Drug application to the China FDA before the end of 2018.
https://thefly.com/landingPageNews.php?id=2829391